Overall, 28 out of 43 patients (65%) whose tumours lacked a genomic match to a clinical trial were eligible for investigational drugs as a result of TMP analysis (PTEN, EGFR, HER2, GPNMB, MSLN, TROP2, TOPO1 or TOP2A as emerging positive predictive markers) (Fig. 3). Here, GPNMB is linked to neoplasm.